- January 3, 2020 at 7:21 pm
IL-2 is one of the older drugs in the melanoma treatment arsenal and can be administered IV as a single agent, used as part of TIL, as well as intralesionally. So, I’m not quite sure which variety you are looking at for your mom. However, if it is IV as a single agent, the data shows that there is only a 10% response rate, though 4-5% of those responses can be durable (lasting over many years). Charlie S on this board is a living testament to how durable this treatment can be!!!
It is a pretty rough haul. It is very basically covered within this primer I put together: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/2017/08/melanoma-intel-primer-for-current.html
However, more recently, IL-2 has been examined as a sequential therapy (both before and after anti-PD-1, for instance) with some positive results! Here are some posts that cover such recent uses:
I hope this helps and wish you and your mom my best. celeste
- January 4, 2020 at 1:55 am
Thank you so much this is really helpful,
Honestly I am not really sure what we exactly we are looking for now, we seem to have already failed couple of therapies .
We still have not figured out what is next- so am trying to do all the research I can before meeting with our oncologist tomorrow.
However, IL-2 intratumor usage seem to be effective with a decent safety profile – so we will see about that and I will keep you guys updated.
Thank you so much!
Something to consider is a new twist to IL-2 called NKTR-214 drug from Nectar Pharma. They have taken the drug IL-2 and pegelated it to make it less toxic, slower acting, which is showing less side effects compared to old school IL-2, they are running a trial where they have combined it with Nivo (Pd-1) drug. Here are a couple of links including a video explaining things in detail by an Oncologist Dr.Adi Diab from MD Anderson as well a link to clinical trial NCT 03635983.https://news.bms.com/press-release/partnering-news/nektar-therapeutics-and-bristol-myers-squibb-announce-us-fda-breakthro https://clinicaltrials.gov/ct2/show/NCT03635983
- January 3, 2020 at 8:31 pm
- January 3, 2020 at 8:31 pm
If you click on link to clinical trial and scroll down to location of trials, you will see that it is a global trial with US, Canada, Australia, Belgium etc participating in this large trial. Most G20 countries have new trials happening with immunotherapy drugs, injectables like Tvec or TLR-9, targeted therapy triplet combinations with Immunotherapy and Til’s trials specific to melanoma. The big problem research is having is getting enough patients to fill the trial due to the fact that the standard of care options are so good now patients aren’t signing up for the research trials like they have in the past when options didn’t exist. Best Wishes!!!Ed
- January 4, 2020 at 2:48 am
jbronickiParticipantI second what Ed has said about trials, the issue is patient enrollment and getting more patients to enroll! It is the single most important variable for clinical trials, can’t do the research without the people! I was at a conference this year where the focus was on this sole issue. I know we enroll patients in multiple countries in our trials, most major trials are international now for multiple reasons: 1) more enrollment due to access to more patients 2) more diversity statistically (there is a lot of research about outcomes across countries and various populations with different demographics) 3) drug approval in multiple countries means larger market
- January 7, 2020 at 1:09 pm
- You must be logged in to reply to this topic.